Biotech · Private company · Houston, TX, US
Bellicum Pharmaceuticals, Inc
SEC CIK 0001358403
Track this companyFree. Adds Bellicum Pharmaceuticals, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials1910 recruiting or active
Pipeline programs23From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline23
- CyclophosphamidePhase 3 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- haplo-HSCTPhase 3 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- rimiducidPhase 3 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- rivogenlecleucelPhase 3 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BPX-501 dose 1Phase 2 · Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BPX-501 dose 2Phase 2 · Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BPX-501 dose 3Phase 2 · Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BPX-501 dose 4Phase 2 · Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BPX-501 T cellsPhase 2 · Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BPX-701Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- RimiducidPhase 2 · Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- SCTPhase 2 · Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- AP1903Phase 1 · Castrate Resistant Prostate Cancer (CRPC)ClinicalTrials.gov · fetched Nov 12, 2026
- AP1903Phase 1 · Hematologic MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- BPX-101Phase 1 · Castrate Resistant Prostate Cancer (CRPC)ClinicalTrials.gov · fetched Nov 12, 2026
- BPX-201 vaccine plus AP1903Phase 1 · Castrate Resistent Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- BPX-501Phase 1 · LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BPX-501Phase 1 · Hematologic MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- BPX-501 and RimiducidPhase 1 · Primary Immune Deficiency DisordersClinicalTrials.gov · fetched Nov 12, 2026
- chimeric antigen receptor (CAR) T cell therapyPhase 1 · HER-2 Gene AmplificationClinicalTrials.gov · fetched Nov 12, 2026
- RimiducidPhase 1 · LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- rimiducidHurler SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- rivogenlecleucelHurler SyndromeClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials19
- Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin LymphomaPHASE2 · NOT_YET_RECRUITING · started Dec 28, 2026ClinicalTrials.gov NCT07164469 · fetched Nov 12, 2026
- Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)PHASE1 · ACTIVE_NOT_RECRUITING · started Dec 2, 2024ClinicalTrials.gov NCT06358430 · fetched Nov 12, 2026
- Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCCPHASE1 · RECRUITING · started Apr 5, 2024ClinicalTrials.gov NCT06096038 · fetched Nov 12, 2026
- Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)PHASE1 · RECRUITING · started Oct 24, 2023ClinicalTrials.gov NCT06066424 · fetched Nov 12, 2026
- Autologous CAR T-Cells Targeting the GD2 Antigen for Lung CancerEARLY_PHASE1 · SUSPENDED · started Jun 21, 2023ClinicalTrials.gov NCT05620342 · fetched Nov 12, 2026
- Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid TumorsPHASE1 · SUSPENDED · started Dec 7, 2020ClinicalTrials.gov NCT04650451 · fetched Nov 12, 2026
- Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory OsteosarcomaPHASE1 · RECRUITING · started Feb 19, 2019ClinicalTrials.gov NCT03721068 · fetched Nov 12, 2026
- Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDSPHASE2_PHASE3 · TERMINATED · started Dec 27, 2018ClinicalTrials.gov NCT03699475 · fetched Nov 12, 2026
- Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal MelanomaPHASE1_PHASE2 · TERMINATED · started Apr 14, 2017ClinicalTrials.gov NCT02743611 · fetched Nov 12, 2026
- Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic TransplantPHASE1 · ACTIVE_NOT_RECRUITING · started Jul 1, 2016ClinicalTrials.gov NCT02477878 · fetched Nov 12, 2026
- Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic MalignanciesPHASE1 · WITHDRAWN · started Jul 1, 2016ClinicalTrials.gov NCT02487459 · fetched Nov 12, 2026
- Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen MesothelinPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 1, 2015ClinicalTrials.gov NCT02414269 · fetched Nov 12, 2026
- Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant DiseasesPHASE1 · TERMINATED · started Feb 1, 2015ClinicalTrials.gov NCT02231710 · fetched Nov 12, 2026
- Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell TransplantPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 1, 2014ClinicalTrials.gov NCT03301168 · fetched Nov 12, 2026
- Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate CancerPHASE1 · COMPLETED · started Apr 1, 2013ClinicalTrials.gov NCT01823978 · fetched Nov 12, 2026
- Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell TransplantPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 1, 2013ClinicalTrials.gov NCT01744223 · fetched Nov 12, 2026
- Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALLPHASE1 · ACTIVE_NOT_RECRUITING · started Mar 22, 2012ClinicalTrials.gov NCT03016377 · fetched Nov 12, 2026
- MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate CancerPHASE1 · COMPLETED · started Apr 1, 2009ClinicalTrials.gov NCT00868595 · fetched Nov 12, 2026
- BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 StudyNO_LONGER_AVAILABLEClinicalTrials.gov NCT03639844 · fetched Nov 12, 2026